16 September 2026 editorial review · Item
Dexcom G8: review notes
These notes document the scope actually reviewed, including source-access limits. They are not independent clinical certification or a guarantee that every claim was verified.
Read the item evidence page →Thriving evidence review — 16 September 2026
Record: Dexcom G8
Scope and findings:
- Read primary May 2026 investor slides29–30: self-adapting electronics/algorithm and late2027/early2028 expected launch. No numeric MARD or cleared product inferred. Detailed submission timing and later conference commentary not independently confirmed.
Primary sources checked:
Limits: The review is restricted to the scopes above. Historical efficacy estimates, editorial scoring and country-specific access were not fully reverified unless expressly stated. A manufacturer or conference report retains that evidence level.
Thriving evidence review — 16 September 2026
Additional second-pass scope: Replaced secondary/syndicated evidence with direct investor slides; removed inherited age2, unconfirmed12-hour grace and unsupported submission specifics. Manufacturer data-on-file improvement distinguished from public numerical accuracy dataset. All scores marked provisional, current access0 and ketones0.
Primary sources checked:
Limits: Only the specific claims and scoring interpretation above were revisited. This does not revalidate every historical outcome or regional access claim.